Dajia Weikang: Hunan Qiyuan Law Firm’s legal opinion on the third extraordinary shareholders’ meeting of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. in 2025
Hunan Qiyuan Law Firm
Legal Opinion on the Third Extraordinary Shareholders Meeting of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. in 2025
November 13, 2025
To: Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Hunan Qiyuan Law Firm (hereinafter referred to as the "Firm") accepted the entrustment of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. (hereinafter referred to as the "Company") and assigned its lawyers to attend the company's third extraordinary shareholders' meeting in 2025 (hereinafter referred to as the "Shareholders' Meeting"). The lawyers witnessed the convening and convening procedures of this shareholders' meeting, the qualifications of the attendees and conveners, the voting procedures and the legality and validity of the voting results, and issued this legal opinion.
Our lawyers issue this legal opinion in accordance with the relevant provisions of the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), the Securities Law of the People's Republic of China (hereinafter referred to as the "Securities Law"), the Rules of Shareholders' Meetings of Listed Companies (hereinafter referred to as the "Shareholders' Meeting Rules") and other current laws, regulations and normative documents in my country, as well as the Articles of Association of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. (hereinafter referred to as the "Articles of Association").
In order to issue this legal opinion, our lawyers declare as follows:
(1) Our lawyers issue this legal opinion based on the company's commitment that the originals of all documents provided to our lawyers and the copies that are consistent with the originals after inspection by our lawyers are true, complete, reliable, and contain no concealments, falsehoods or major omissions.
(2) The lawyers of our firm have followed the principles of diligence and good faith, strictly performed their statutory duties, fully verified the facts that have occurred or existed before the date of issuance of this legal opinion, and ensured that the facts identified in this legal opinion are true, accurate, and complete, and that the concluding opinions issued are legal and accurate, and there are no false records, misleading statements, or major omissions.
(3) Our lawyers have not authorized any unit or individual to make any interpretation or explanation of this legal opinion.
In order to issue this legal opinion, our lawyers have checked the following information provided by the company in accordance with the law:
Notices and other announcements related to this shareholders’ meeting published on the Shenzhen Stock Exchange website (http://www.szse.cn/);
Identity documents, power of attorney, etc. of shareholders or their agents attending the meeting;
The company’s shareholder list on the equity registration date of this shareholders’ meeting;
Statistical results of online voting;
Documents, voting materials, etc. of this shareholders’ meeting.
In view of this, our lawyers have issued the following legal opinions on this shareholders’ meeting in accordance with the recognized business standards, ethics and diligence of the legal industry:
1. Convening and convening procedures of this shareholders’ meeting
(1) After verification, this shareholders' meeting was convened by the company's board of directors. The company's board of directors announced the "Notice of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. on convening the third extraordinary shareholders' meeting in 2025" on October 28, 2025 on the media designated by the China Securities Regulatory Commission and the website of the Shenzhen Stock Exchange (http://www.szse.cn/). The notice announced the time, location, method, content of proposals, meeting registration methods and other matters of the meeting.
(2) This shareholders’ meeting will be held through a combination of on-site voting and online voting.
The on-site shareholders' meeting will be held at 2:30 pm on November 13, 2025 in the conference room on the third floor of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd., No. 30 Fuling Road, Yuelu District, Changsha.
The specific time for voting at this shareholders' meeting through the Shenzhen Stock Exchange's Internet voting system is: 9:15 to 15:00 on November 13, 2025; the time for online voting through the Shenzhen Stock Exchange's trading system is: November 13, 2025 9:15-9:25, 9:30-11:30 and 13:00-15:00.
After verification, the time, place, method, and content of the shareholders' meeting were consistent with the meeting notice and announcement.
The Exchange believes that the convening and convening procedures of this shareholders' meeting comply with the provisions of the "Company Law", "Shareholders' Meeting Rules" and other laws, regulations and normative documents, as well as the "Articles of Association".
2. Qualifications of the convener of this shareholders’ meeting and those attending the meeting
(1) On-site meeting
After verification, a total of 4 shareholders and shareholders' agents attended the on-site shareholders' meeting. They were all shareholders or their legally authorized agents registered in the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. on the equity registration date determined by the company's board of directors. They held a total of 97,881,875 shares, accounting for 47.6535% of the company's total shares with voting rights.
After inspection, in addition to the above-mentioned shareholders and shareholders' agents, the company's current directors, board secretaries, etc. and lawyers of the firm also attended the shareholders' meeting. These personnel have the qualifications to attend the meeting as stipulated in laws, regulations and the "Articles of Association".
The Exchange believes that the qualifications of the personnel attending this on-site shareholders meeting are legal and valid.
(2) Online voting
According to online voting statistics, a total of 80 shareholders participated in this shareholders' meeting through online voting, holding a total of 332,200 shares of the company, accounting for 0.1617% of the company's total shares with voting rights.
(3) Qualifications of meeting convener
This shareholders' meeting is convened by the company's board of directors.
The Exchange believes that the qualifications of the convener of this shareholders’ meeting are legal and valid.
3. Temporary proposals for this shareholders’ meeting
After verification, there are no temporary proposals at this shareholders' meeting.
4. Voting procedures and results of this shareholders’ meeting
(1) On-site meeting
After verification, the on-site shareholders' meeting was voted by on-site registered voting. Before the shareholders' meeting votes on the proposal, two shareholder representatives are elected to participate in the counting and supervision of votes. Shareholders and shareholders' proxies present at the meeting reviewed and voted on the proposals included in the agenda of this shareholders' meeting. After the voting, the shareholder representatives elected by the meeting and our lawyers are jointly responsible for counting and supervising the votes.
(2) Online voting
After the online voting ended, the company tallied the online voting results of this shareholder meeting.
(3) Voting results
After the online voting of this shareholders’ meeting ended, the company combined the results of the on-site voting and online voting (hereinafter referred to as the “total voting results”). The total voting results and the voting results of small and medium-sized investors other than shareholders who individually or collectively hold more than 5% of the company's shares (hereinafter referred to as the "voting results of small and medium-sized investors") are as follows:
- Considered and approved the "Proposal on the Resignation of Independent Directors upon Expiration of their Term and the By-Election of Independent Directors and Members of Special Committees of the Board of Directors"
The combined voting results were: 98,141,975 shares were approved, accounting for 99.9266% of the total number of shares with valid voting rights represented by shareholders participating in the vote; 60,600 shares were opposed, accounting for 0.0617% of the total number of shares with valid voting rights represented by shareholders participating in the voting; 11,500 abstentions shares (0 shares abstained by default due to non-voting), accounting for 0.0117% of the total number of shares with valid voting rights represented by shareholders participating in the voting.
Voting results of small and medium investors: 260,100 shares were approved, accounting for 78.2962% of the total number of shares with valid voting rights represented by small and medium-sized shareholders participating in the vote; 60,600 shares were opposed, accounting for 18.2420% of the total number of shares with valid voting rights represented by small and medium-sized shareholders participating in the voting; 11,500 abstentions shares (of which 0 shares abstained by default due to non-voting), accounting for 3.4618% of the total number of shares with valid voting rights represented by the small and medium-sized shareholders participating in the voting.
- Reviewed and approved the “Proposal on Profit Distribution Plan for the First Three Quarters of 2025”
The combined voting results were: 98,135,675 shares were approved, accounting for 99.9202% of the total number of shares with valid voting rights represented by shareholders participating in the vote; 67,700 shares were opposed, accounting for 0.0689% of the total number of shares with valid voting rights represented by shareholders participating in the voting; 10,700 abstentions shares (0 shares abstained by default due to non-voting), accounting for 0.0109% of the total number of shares with valid voting rights represented by shareholders participating in the voting.
Voting results of small and medium investors: 253,800 shares were approved, accounting for 76.3998% of the total number of shares with valid voting rights represented by small and medium-sized shareholders participating in the vote; 67,700 shares were opposed, accounting for 20.3793% of the total number of shares with valid voting rights represented by small and medium-sized shareholders participating in the voting; 10,700 abstentions shares (of which 0 shares abstained by default due to non-voting), accounting for 3.2210% of the total number of shares with valid voting rights represented by the small and medium-sized shareholders participating in the voting.
We believe that the voting procedures and results of this shareholders’ meeting are legal and valid.
5. Conclusions
In summary, the Exchange believes that the convening and convening procedures of this shareholders’ meeting comply with the provisions of the Company Law, the Rules of Shareholders’ Meetings and other laws, regulations, normative documents, and the Articles of Association; the qualifications of the persons attending the shareholders’ meeting and the qualifications of the convener of the meeting are legal and valid; the voting procedures and voting results of this shareholders’ meeting are legal and valid.
(There is no text below this page, the next page is the signature page)
(This page has no text, but is the signature and seal page of "Hunan Qiyuan Law Firm's Legal Opinion on the Third Extraordinary Shareholders Meeting of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. in 2025") Hunan Qiyuan Law Firm
Person in charge: Handling lawyer:
Handling lawyer:
Signing date: year month day